BGM Group (NASDAQ:BGM - Get Free Report) was upgraded by Wall Street Zen to a "buy" rating in a note issued to investors on Saturday.
BGM Group Stock Down 2.5%
BGM traded down $0.27 on Friday, hitting $10.32. The company had a trading volume of 38,416 shares, compared to its average volume of 34,094. The company's fifty day moving average price is $12.56 and its 200 day moving average price is $10.96. BGM Group has a 1 year low of $5.26 and a 1 year high of $17.17.
BGM Group Company Profile
(
Get Free Report)
Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions.
Featured Stories
Before you consider BGM Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BGM Group wasn't on the list.
While BGM Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
